FDA approves Bard's Lutonix DEB

The FDA grants pre-market approval for C.R. Bard's Lutonix drug-eluting balloon for treating peripheral artery disease.

C.R. Bard (NYSE:BCR) said today that the FDA granted pre-market approval for its Lutonix drug-eluting balloon for treating peripheral artery disease, well ahead of the company's expectation for approval early next year.

C.R. Bard, Food & Drug Administration (FDA)

News Well, Peripheral Artery Disease, Pre-Market Approval (PMA), Regulatory/Compliance

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1s2E8BQ